Work

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors

Year: 2014

Type: article

Study design: Clinical Trial

Source: Journal of Thoracic Oncology

DOI: 10.1097/jto.0000000000000088

Authors: Pasi A. Jänne, Roger B. Cohen, A. Douglas Laird, Sandrine Macé, Jeffrey A. Engelman, Rodrigo Ruiz-Soto, Kevin Rockich, Jianbo Xu, Geoffrey I. Shapiro, Pablo Martinez, Enriqueta Felip

Institutions: Fox Chase Cancer Center, Exelixis (United States), Massachusetts General Hospital, Dana-Farber Cancer Institute, Sanofi (France), Sanofi (United States), Vall d'Hebron Hospital Universitari

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Sanofi, Exelixis, Clovis Oncology, Agios Pharmaceuticals, William Guy Forbeck Research Foundation, Daiichi-Sankyo, Fondazione Pezcoller, Genentech, Chugai Pharmaceutical

OpenAlex ID: W1997870023

FWCI: 2.433

Cites: 22

Cited by: 49

Related to: 10